Oryzon Secures U.S. Patent for Iadademstat-Gilteritinib Combo in AML — Oryzon Genomics, S.A.

Event summary

Oryzon received a Notice of Allowance from the USPTO for a patent covering iadademstat in combination with gilteritinib for treating myeloid cancers, including AML.
The patent is expected to expire in 2042, with additional patent applications pending in other jurisdictions.
Iadademstat plus gilteritinib achieved a 67% composite complete remission (CRc) rate in heavily pretreated FLT3-mutated relapsed/refractory AML patients.
Oryzon also reported a 100% overall response rate in the ALICE-2 study combining iadademstat with venetoclax and azacitidine in first-line AML.

The big picture

Oryzon's patent win strengthens its intellectual property moat in the competitive AML space, where combination therapies are increasingly becoming the standard of care. The strong clinical data from FRIDA and ALICE-2 position iadademstat as a key player in both relapsed/refractory and first-line settings, potentially expanding its market reach. The company's broader patent portfolio covering other AML combinations further reinforces its long-term strategy in oncology.

What we're watching

Patent Protection: The long-term validity of this patent and its ability to shield Oryzon's market position in AML combination therapies.
Clinical Validation: The pace at which additional mature data from the FRIDA and ALICE-2 studies will solidify iadademstat's clinical profile.
Regulatory Pathway: Whether Oryzon can leverage these results to initiate a potentially registrational study in first-line AML.